# BTAI — BioXcel Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BTAI  
**Sources:** 26  
**Published:** 2026-08-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-btai-bioxcel-therapeutics-inc-catalysts-narrative-risks-2753

---

# BioXcel Therapeutics Inc. (BTAI) — Research Summary as of August 28, 2026

## Overview

BioXcel Therapeutics is a biopharmaceutical company focused on neuroscience and immuno-oncology, utilizing AI-driven drug development approaches [[26]](https://www.bioxcel.com/). Its lead product is IGALMI (BXCL501), a sublingual film for acute agitation, and it has an oncology pipeline asset, BXCL701, targeting aggressive prostate cancer and other tumors [[23]](https://www.bioxceltherapeutics.com/our-pipeline/)[[24]](https://www.bioxceltherapeutics.com/our-pipeline/). The stock currently trades at approximately $0.72 per share with a market capitalization of roughly $23.79 million, firmly in sub-micro-cap territory [[12]](https://seekingalpha.com/symbol/BTAI)[[13]](https://marketchameleon.com/Overview/BTAI/Summary/).

---

## Key Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-btai-bioxcel-therapeutics-inc-catalysts-narrative-risks-2753 (free to sign up)._